Infinity Pharmaceuticals, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 16 rows in 2019. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2019-10-16: Reporting owner Agresta Samuel; Form 3; Security Stock Option (right to buy); Transaction Holding.
- 2019-10-16: Reporting owner Agresta Samuel; Form 3; Security Stock Option (right to buy); Transaction Holding.
- 2019-06-13: Reporting owner EVNIN ANTHONY B; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2019-06-13: Reporting owner SELBY NORMAN C; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2019-10-16 holding as of filing | Agresta Samuel Director | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $1.80 exercise price | 2019-10-16 | ||
| 2019-10-16 holding as of filing | Agresta Samuel Director | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $1.24 exercise price | 2019-10-16 | ||
| 2019-06-13 | EVNIN ANTHONY B Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $1.60 exercise price | 2019-06-14 | |
| 2019-06-13 | SELBY NORMAN C Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 0 owned after | $1.60 exercise price | 2019-06-14 | |
| 2019-06-13 | SELBY NORMAN C Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 0 owned after | $1.60 exercise price | 2019-06-14 | |
| 2019-06-13 | BEIER DAVID W Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $1.60 exercise price | 2019-06-14 | |
| 2019-06-13 | VENUTI MICHAEL C Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $1.60 exercise price | 2019-06-14 | |
| 2019-06-13 | BLOCH LAWRENCE E Officer (President) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $1.24 exercise price | 2019-06-14 | |
| 2019-06-13 | Kauffman Michael Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $1.60 exercise price | 2019-06-14 | |
| 2019-06-13 | Perkins Adelene Q Director, Officer (Chief Executive Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +242,000 242,000 owned after | $1.24 exercise price | 2019-06-14 | |
| 2019-06-13 | Berkowitz Jeffrey Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $1.60 exercise price | 2019-06-14 | |
| 2019-01-04 | Tasker Seth A Officer (General Counsel) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +140,000 140,000 owned after | $1.24 exercise price | 2019-01-07 | |
| 2019-01-04 | BLOCH LAWRENCE E Officer (President) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +335,000 335,000 owned after | $1.24 exercise price | 2019-01-07 | |
| 2019-01-04 | Kutok Jeffery Officer (Chief Scientific Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +155,000 155,000 owned after | $1.24 exercise price | 2019-01-07 | |
| 2019-01-04 | Agresta Samuel Officer (Chief Medical Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +62,596 62,596 owned after | $1.24 exercise price | 2019-01-07 | |
| 2019-01-04 | Perkins Adelene Q Director, Officer (Chief Executive Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +243,000 243,000 owned after | $1.24 exercise price | 2019-01-07 |